William Blair Comments on argenx’s Q4 Earnings (NASDAQ:ARGX)

argenx SE (NASDAQ:ARGX) – Equities researchers at William Blair issued their Q4 2026 earnings estimates for argenx in a report released on Monday, March 17th. William Blair analyst M. Minter expects that the company will earn $7.29 per share for the quarter. William Blair has a “Outperform” rating on the stock. The consensus estimate for argenx’s current full-year earnings is $3.13 per share.

Other equities analysts have also recently issued research reports about the stock. Sanford C. Bernstein upgraded shares of argenx from a “market perform” rating to an “outperform” rating in a research report on Monday. Citigroup reiterated an “outperform” rating on shares of argenx in a research note on Friday, February 28th. Oppenheimer increased their target price on argenx from $675.00 to $704.00 and gave the stock an “outperform” rating in a research note on Friday, February 28th. Piper Sandler lifted their price target on argenx from $620.00 to $725.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 7th. Finally, JMP Securities increased their price target on shares of argenx from $606.00 to $696.00 and gave the company a “market outperform” rating in a report on Tuesday, January 14th. Three investment analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $687.00.

argenx Stock Performance

Shares of ARGX stock opened at $619.97 on Tuesday. argenx has a fifty-two week low of $349.86 and a fifty-two week high of $678.21. The firm has a market cap of $37.67 billion, a P/E ratio of -704.51 and a beta of 0.59. The business’s 50 day moving average price is $636.24 and its 200-day moving average price is $598.37.

argenx (NASDAQ:ARGX) last posted its earnings results on Thursday, February 27th. The company reported $1.58 earnings per share for the quarter, topping analysts’ consensus estimates of $0.98 by $0.60. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The company had revenue of $761.22 million during the quarter, compared to analyst estimates of $678.52 million.

Institutional Trading of argenx

A number of large investors have recently modified their holdings of ARGX. FMR LLC raised its position in argenx by 17.2% during the 4th quarter. FMR LLC now owns 5,618,222 shares of the company’s stock valued at $3,455,207,000 after purchasing an additional 824,750 shares in the last quarter. Janus Henderson Group PLC raised its holdings in shares of argenx by 0.4% in the third quarter. Janus Henderson Group PLC now owns 2,479,207 shares of the company’s stock valued at $1,343,797,000 after acquiring an additional 10,975 shares in the last quarter. Capital World Investors lifted its stake in argenx by 5.1% in the fourth quarter. Capital World Investors now owns 1,786,936 shares of the company’s stock worth $1,099,002,000 after acquiring an additional 86,687 shares during the period. RTW Investments LP grew its holdings in argenx by 2.9% during the 4th quarter. RTW Investments LP now owns 673,497 shares of the company’s stock worth $414,201,000 after acquiring an additional 19,067 shares in the last quarter. Finally, Clearbridge Investments LLC increased its position in argenx by 6.8% during the 4th quarter. Clearbridge Investments LLC now owns 629,828 shares of the company’s stock valued at $387,344,000 after purchasing an additional 40,330 shares during the period. Hedge funds and other institutional investors own 60.32% of the company’s stock.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.